A Phase 1 Study Of Tp-3654, An Orally-Delivered Pim Kinase Inhibitor, In Patients With Intermediate-2 Or High-Risk Primary Or Secondary Myelofibrosis

BLOOD(2020)

引用 3|浏览8
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要